Common Stock, par value $0.001 per share
- Symbol
- AVXL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Anavex Life Sciences Corp.
AVXLNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On July 20, 2026, Anavex Life Sciences Corp. (the “Company”) timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Ex…
Company context
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 3, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsNov 2, 2026
- Other EventsOct 20, 2026
- Other EventsOct 15, 2026
- Changes in Control of Registrant · Submission of Matters to a Vote of Security HoldersSep 28, 2026
Registered securities in this filing
ANAVEX LIFE SCIENCES CORP. · 8-K · Filed 2026-07-20
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On July 20, 2026, Anavex Life Sciences Corp. (the “Company”)
timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”)
of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file
all required periodic financial reports with the Securities and Exchange Commission (“Rule 5250(c)(1)”). As previously disclosed,
on May 20, 2026, the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff indicating that,
as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31,
2026, it is not in compliance with Rule 5250(c)(1).
The Notice has no immediate effect on the listing of the Company’s
common stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.
The Compliance Plan is currently under review by the Nasdaq Staff. If the
Compliance Plan is accepted by the Nasdaq Staff, the Nasdaq Staff may grant an extension for the Company to regain compliance. If the
Compliance Plan is not accepted by the Nasdaq Staff, the Company will have an opportunity to request a hearing on the Nasdaq Staff’s
determination before an independent Hearings Panel.